➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,383,884

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,383,884 protect, and when does it expire?

Patent 10,383,884 protects NUZYRA and is included in two NDAs.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 10,383,884
Title:9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Inventor(s): Tzanis; Evangelos L. (Newtown Square, PA), McGovern; Paul (Berwyn, PA), Manley; Amy L. (Phoenixville, PA), Garrity-Ryan; Lynne (Melrose, MA), Tanaka; S. Ken (Bellevue, WA)
Assignee: Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:15/798,573
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 10,383,884

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA   Start Trial
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,383,884

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2017353588   Start Trial
Brazil 112019008897   Start Trial
Canada 3042514   Start Trial
China 110087655   Start Trial
European Patent Office 3534908   Start Trial
Japan 2019532976   Start Trial
Mexico 2019005070   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.